The use of specific biomarkers of glomerular damage, inflammation, fibrosis, or immunological activity could help to better clarify whether SGLT2 inhibitors are “simply” nephroprotective agents or have beneficial effects specific to glomerulonephritis or, more broadly, to autoimmune disease. The gene discussed is SLC5A2; the disease is autoimmune disease.